FACTBOX: Smaller drug firms gaining from swine flu

(Reuters) - The outbreak of swine flu that is suspected to have already killed 149 people in Mexico has boosted shares of a few companies -- ranging from vaccine developers to makers of disinfectants -- that could gain from attempts to control it.

Here is a summary of the top gainers Monday and some relevant facts about the companies.

* Novavax Inc (NVAX.O), a small viral vaccine maker, saw its shares rise as much as 173 percent.

-- Product : The company is currently running mid-stage trials on two vaccines that target seasonal influenza and the H5N1 flu strain.

-- Market Cap : $115.7 million, with 81.5 million shares outstanding as of April 13

-- Main Investors : Rajiv Modi (director), OppenheimerFunds Inc, Wellington Management Co LLP

-- Short Interest Ratio : About 2.7 percent of the stock outstanding was held in a short position as of April 13

* Shares of flu drug maker Biocryst Pharmaceuticals Inc (BCRX.O) rose as much as 122 percent.

-- Product : One of its drug candidates, peramivir, which is in mid-stage trials, is being developed as a treatment for influenza.

-- Market Cap : $84.7 million, with 38.3 million shares outstanding as of March 6

-- Main Investors : Baker Brothers Advisors, William Featheringill

-- Short Interest Ratio : About 2 percent of the stock was held in a short position as of March 6

* DNA-based vaccines maker Vical Inc (VICL.O) saw its shares rise about 30 percent.

-- Product : Vical has completed the early-stage trials for its candidate in the prevention of H5N1 influenza virus.

-- Market Cap : $102.1 million, with 40.4 million shares outstanding as of March 23

-- Main Investors : Temasek Holdings Private Ltd, James Singer